Triferic
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
Sep 1, 2020 → Nov 1, 2023
NCT ID
NCT04239391About Triferic
Triferic is a phase 3 stage product being developed by Rockwell Medical for End Stage Renal Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT04239391. Target conditions include End Stage Renal Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04239391 | Phase 3 | UNKNOWN |
| NCT04409132 | Phase 1/2 | Completed |
| NCT03303144 | Phase 1/2 | Completed |
| NCT02909153 | Phase 1 | Completed |
| NCT02739100 | Phase 1 | Completed |
| NCT02595437 | Phase 1/2 | Completed |
| NCT02636049 | Phase 1 | Completed |
Competing Products
20 competing products in End Stage Renal Disease